The Odisha market grew the highest at 17.9 per cent followed by Bihar and South Maharashtra
The Indian Pharmaceutical Market (IPM) clocked Rs 9125 crores in July 2016 and has grown at 9.5 per cent. Amongst the top 10, Mankind grew at 20.4 per cent, Macleods at 19 per cent followed by Alkem at 14.9 per cent. 22 corporate have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporates, Indoco had the highest growth of 27.8 per cent followed by Aristo at 24.5 per cent and Hetero at 24.2 per cent. 21 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Aristo had the highest growth of 24.5 per cent followed by Sanofi at 20.6 per cent and Alembic at 18 per cent.
Amongst the 21-30 ranked corporate, Indoco had the highest growth at 27.8 per cent followed by Ipca at 18.1 per cent and Unichem at 17.3 per cent. Amongst the 31-40 ranked corporates, Bharat Serums grew at 23.3 per cent followed by JBCPL at 20.1 per cent and Franco at 16.5 per cent. Amongst the 41-50 ranked corporates, Hetero has the highest growth at 24.2 per cent followed by Medly & Apex at 22.8 per cent. Amongst the 51-60 ranked corporates, Centaur grew at 44.1 per cent followed by Corona at 36 per cent and Boehringer at 32.3 per cent. Amongst the 61-70 ranked corporates, Shreya grew at 32.6 per cent followed by Tablets India at 21 per cent and Biological E at 15.7 per cent.
Amongst the 71-80 ranked corporates, Dabur grew by 48.4 per cent followed by Samarth at 38.8 per cent and Danone at 30.7 per cent. Amongst the 81 -90 ranked corporates, Veritaz grew at 48.6 per cent followed by Galpha at 34.4 per cent and Natco at 33.2 per cent. Amongst the 91 -100 ranked corporates, Dey’s Medical grew at 38.2 per cent, Gland at 29.4 per cent and Unison at 21.2 per cent.
Amongst the 101-150 few of the fastest growing corporates include Aglowmed, Claris, La Renon, Obsurge, Delcure, Icon & Comed. The 100th biggest corporate was Unison and 150th biggest corporate was Karnataka Antibiotics in the IPM. Curatio entered the Rs 100-crore club on MAT Basis.
Abbott HC grew at 4.6 per cent whereas Abbott India grew at 3.2 per cent in July 2016. Zuventus grew at 21.4 per cent. Indian companies have grown at 10.9 per cent versus 5 per cent for MNCs. Amongst the top 50 in MNCs, Sanofi grew at 20.6 per cent followed by AstraZeneca at 8.3 per cent and Janssen at 8.2 per cent. Under the Non-NLEM category, Indian companies grew at 3.8 per cent whereas MNCs grew at -4.2 per cent.
The NLEM 2013 containing molecules market grew at 1.6 per cent whereas the Non-NLEM market grew by 11.2 resulting in an overall growth of 9.5 per cent. NLEM and Non – NLEM category showed unit growth of 11 per cent and 4.2 per cent respectively.
From therapy perspective, eight therapies have outgrown the IPM growth. The respiratory market grew at 27.2 per cent, gastrointestinal market grew at 8.4 per cent, pain and analgesics market grew at 9.8 per cent whereas the anti-infectives grew at 14.9 per cent. The anti-diabetic market grew at 10.1 per cent and cardiac at 5.2 per cent, neuro/ CNS at 1.9 per cent in chronic business. The anti-malarials grew at 27.7 per cent and VMS market at 4.8 per cent. The derma market grew by 5.8 per cent followed by the urology market at eight per cent.
From regional perspective, 15 regions have outgrown the IPM growth. The Odisha market grew the highest at 17.9 per cent followed by Bihar market at 16.1 per cent and South Maharashtra market at 15.4 per cent. No regions had a negative growth in the said month.
Amoxycillin + Clavulanic Acid market grew at 15.6 per cent and Glimepiride + Metformin market grew at 20.2 per cent. The markets of paracetamol grew at 44.8 per cent, Atorvastatin 14.7 per cent, probiotic microbes at 25.6 per cent, Bacillus Clausii market at 31.1 per cent, Cefixime at 19.7 per cent, Pantoprazole at 12.1 per cent, Montelukast + Levocetrizine at 34.2 per cent, Glimepiride + Metformin + Pioglitazone at -19.7 per cent, Vitamin-D at 2.1 per cent, Hydroquinone + Mometasone + Tretinoin at -2.1 per cent, Voglibose + Metformin + Glimepiride at 32.9 per cent, Rosuvastatin at 11 per cent, protein supplements at 11.1 per cent, Azithromycin at 19.3 per cent, calcium carbonate + Vit D3 market at -5.7 per cent, paracetamol + Phenylephrine + Chlorpheniramine at 56.6 per cent, Meropenem at 25.1 per cent, Montelukast + Fexofenadine at 29.5 per cent, Diclofenac at 12.2 per cent, Telmisartan at -12.4per cent, Levetiracetam at 7.6 per cent.
Mixtard led the pack with Rs 40 crores followed by Glycomet GP at Rs 33 crores, Lantus at Rs 27 crores and Monocef at Rs 29 crores for July 2016. Few Brands who have gained ranks include Monocef O (+61), Minipress XL (+49), Rotarix (+47), Ecosprin AV (+42), Sinarest (+38), Ascoril Plus (+30), Calpol, Allegra (+28), Gluconorm G (+25), Zifi, Revital H (+23), Duolin (+22), Meronem, Trajenta (+21), Clexane (+20), Budeocrt, Udiliv, Mifegest Kit (+18), Combiglam, Mikacin (+16), Mox (+15), Januvia (+11), Dolo, Mucaine (+10), Zinetac (+8), Levipil, Rantac (+7), Clavam (+6), Lantus, Novomix, Zoryl M (+5), Monocef, Rosuvas, Gemer (+4), Pan D, Eltroxin (+3), amongst top 100 Brands over July 2015.
Grilinctus, Hucog HP, Glimestar M, Febrex Plus, P, Cilacar, Sumo, Lonopin, Budamate, Cyclopam are few brands which gained ranks in 101-200 ranked brands.
A few of the brands which moved up fastest into Top 300 brands were Forxiga, Grilinctus BM, Mifty, Imicrit, Trajenta Duo, Gudcef, Hucog HP, Corex Dx, Maxtra, Placentrex. The 300th biggest brand was Maxtra from Zuventus
A total of 431 brands and 744 SKUs were launched in July 2016. The top five new brands were Priorix Tetra, Lulibet, Novefos, Sovaldi, Lulican. The biggest launch by MNC was Priorix Tetra by GSK. Five brands were launched each in Teneligliptin containing market, three brands each in Carica Papaya Market and Luliconazole market.
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com